RESUMEN
In structure of the complicated forms of a stomach ulcer gastroenteric bleedings make 42-47%. Practically all of them are accompanied by development sharp an anemias. At an out-patient stage at patients with a stomach ulcer complicated gastrointestinal bleeding, the doctor is engaged in correction. However, the question of indemnification anemias remains more often without attention though, from modern positions of specialized treatment of a stomach ulcer, also demands the specialized approach for optimum terms of rehabilitation of patients.
Asunto(s)
Anemia/prevención & control , Hemorragia Gastrointestinal/cirugía , Coagulación con Láser , Láseres de Gas/uso terapéutico , Úlcera Gástrica/cirugía , Enfermedad Aguda , Anemia/sangre , Anemia/etiología , Transfusión Sanguínea , Recuento de Eritrocitos , Hemorragia Gastrointestinal/sangre , Hemorragia Gastrointestinal/complicaciones , Hematócrito , Hemoglobinas/análisis , Humanos , Masculino , Recuento de Reticulocitos , Úlcera Gástrica/sangre , Úlcera Gástrica/complicaciones , Resultado del TratamientoRESUMEN
The evaluation of the biological and epidemiological properties of Ebola, Marburg, Lassa, and Machupo viruses suggests that they are of social importance for health care authorities. The studies have created prerequisites to the development of reliable biosafety means against these pathogens. Particular emphasis is laid on the methods for infection diagnosis and on the studies to design specific protective agents--immunoglobulins and inactivated vaccines.
Asunto(s)
Arenavirus del Nuevo Mundo/patogenicidad , Brotes de Enfermedades , Ebolavirus/patogenicidad , Fiebre Hemorrágica Americana , Fiebres Hemorrágicas Virales , Virus Lassa/patogenicidad , Marburgvirus/patogenicidad , Animales , Especificidad de Anticuerpos/inmunología , Antígenos Virales/administración & dosificación , Antivirales/uso terapéutico , Arenavirus del Nuevo Mundo/inmunología , Ebolavirus/inmunología , Salud Global , Fiebre Hemorrágica Americana/epidemiología , Fiebre Hemorrágica Americana/patología , Fiebre Hemorrágica Americana/terapia , Fiebres Hemorrágicas Virales/epidemiología , Fiebres Hemorrágicas Virales/patología , Fiebres Hemorrágicas Virales/terapia , Caballos , Humanos , Inmunización , Inmunoglobulinas/inmunología , Inmunoglobulinas/uso terapéutico , Infección de Laboratorio/epidemiología , Virus Lassa/inmunología , Marburgvirus/inmunología , Ribavirina/uso terapéutico , Vacunas Virales/administración & dosificación , VirulenciaRESUMEN
The use of guinea pigs as a laboratory model was proven to be appropriate in investigating the vaccines developed against Lassa fever at the preclinical study stage. An adapted variant of Lassa virus was cultivated, which caused death of guinea pigs with respect for an agent's dose. Finally, it was shown to be possible to investigate the immunogenic and protective properties of the inactivated antigen of Lassa virus in experiments with guinea pigs.
Asunto(s)
Fiebre de Lassa/prevención & control , Vacunas Virales/administración & dosificación , Animales , Antígenos Virales/inmunología , Femenino , Cobayas , Virus Lassa/inmunología , Masculino , Vacunas Virales/inmunologíaRESUMEN
Hybridomas producing monoclonal antibodies (MAb) to Marburg virus glycoprotein were prepared by splicing of mouse myeloma cells (NSO and X.63-Ag6.653 strains) and splenocytes of immunized BALB/c mice. Cultural and MAb-producing properties of hybridomas were studied. The production of MAb during serial passages 15-30 was confirmed. MAb titers in culture fluids were 1:4096-1:8152, in immune ascitic fluids of BALB/c mice 1:409,600-1:638,400. The possibility of using MAbs as a component of ELISA test system was demonstrated. The sensitivity of ELISA-MAb method for Marburg virus was 1 x 10(3) PFU/mu.
Asunto(s)
Anticuerpos Monoclonales/biosíntesis , Hibridomas/inmunología , Marburgvirus/inmunología , Proteínas del Envoltorio Viral/inmunología , Proteínas Estructurales Virales/inmunología , Animales , Ensayo de Inmunoadsorción Enzimática , Ratones , Ratones Endogámicos BALB C , Pase SeriadoRESUMEN
The authors validate the efficiency of pathogenetic approach to the development of urgent measures for the prevention and therapy of Ebola fever. The virus circulating in the body is to be blocked as soon as possible and the impaired functions and systems repaired. Therapy of Ebola fever should be based on the earliest possible and sufficiently prolonged administration of specific immunoglobulins in combination with pathogenetic drugs.
Asunto(s)
Fiebre Hemorrágica Ebola/prevención & control , Fiebre Hemorrágica Ebola/terapia , Inmunización Pasiva , Animales , Antivirales/uso terapéutico , Cobayas , Fiebre Hemorrágica Ebola/tratamiento farmacológico , Papio , PlacebosRESUMEN
The protective properties of early virus-specific proteins (EVSP) of Marburg virus have been studied. Immunoglobulins to EVSP in combination with immunoglobulins to UV-inactivated Marburg virus prevented lethal infection in Marburg virus infected guinea pigs. More than 80% of guinea pigs immunized by mixture of EVSP and UV-inactivated Marburg virus survived after challenge with 25 LD50 of Marburg virus. The explanation of this phenomenon and its further utilization are discussed.